Quanterix Releases Financial Results for the Second Quarter of 2025
“Through our combination with Akoya Biosciences, we have created a high-margin, high-throughput business with a compelling opportunity to deliver profitable growth in an expanded market,” said Masoud Toloue, CEO of Quanterix. “We have built a franchise that is generating approximately
“We took decisive actions to position the business for long-term growth while driving cost reductions, capturing efficiencies and advancing key strategic initiatives,” Toloue continued. “As of today, we have already captured
Second Quarter Financial Highlights
-
Revenue of
$24.5 million 29% compared to$34.4 million
-
GAAP gross margin of
46.2% , as compared to64.7% in the prior year. Adjusted gross margin (non-GAAP) of41.8% as compared to58.6% in the prior year.
-
Net loss of
$30.0 million $7.4 million
-
The Company ended the second quarter with
$263.8 million $5.7 million $2.6 million $5.1 million
Operational and Business Highlights
- Completed the acquisition of Akoya Biosciences in early July, creating the first integrated platform capable of measuring biomarkers across the blood and tissue continuum.
- Launched p-Tau 205 and p-Tau 212 Assays to Advance Alzheimer’s Research at the Alzheimer’s Association International Conference (AAIC).
- Announced that Quanterix’s UltraDx Plasma pTau-217 Assay Kit (Single-Molecule Immunofluorescence) has successfully obtained medical device registration approval from the National Medical Product Agency (i.e. China’s FDA).
- Continued to build the foundation for Alzheimer’s diagnostics by forming new partnerships, expanding international regulatory footprint, and increasing test volumes and revenues.
2025 Full Year Business Outlook
In assessing recent weakness in the
Quanterix expects GAAP gross margin to be in the range of
Conference Call
In conjunction with this announcement, the Company will host a conference call on August 7, 2025, at 4:30 PM E.T. The dial-in number for
Interested investors can also listen to the live webcast from the Event Details page in the Investors section of the Quanterix website at https://ir.quanterix.com. An archived webcast replay will be available on the Company’s website for one year.
About Quanterix
Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,400 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at www.quanterix.com.
Financial Highlights
QUANTERIX CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS (amounts in thousands, except per share data, unaudited) |
|||||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
Revenues: |
|
|
|
|
|
|
|
||||||||
Product revenue |
$ |
16,832 |
|
|
$ |
19,887 |
|
|
$ |
37,572 |
|
|
$ |
39,557 |
|
Service and other revenue |
|
7,090 |
|
|
|
13,511 |
|
|
|
15,853 |
|
|
|
25,478 |
|
Collaboration and license revenue |
|
532 |
|
|
|
729 |
|
|
|
1,303 |
|
|
|
884 |
|
Grant revenue |
|
22 |
|
|
|
254 |
|
|
|
82 |
|
|
|
528 |
|
Total revenues |
|
24,476 |
|
|
|
34,381 |
|
|
|
54,810 |
|
|
|
66,447 |
|
Costs of goods sold and services: |
|
|
|
|
|
|
|
||||||||
Cost of product revenue |
|
9,295 |
|
|
|
6,670 |
|
|
|
19,059 |
|
|
|
14,907 |
|
Cost of service and other revenue |
|
3,881 |
|
|
|
5,477 |
|
|
|
8,035 |
|
|
|
10,758 |
|
Total costs of goods sold and services |
|
13,176 |
|
|
|
12,147 |
|
|
|
27,094 |
|
|
|
25,665 |
|
Gross profit |
|
11,300 |
|
|
|
22,234 |
|
|
|
27,716 |
|
|
|
40,782 |
|
Operating expenses: |
|
|
|
|
|
|
|
||||||||
Research and development |
|
9,081 |
|
|
|
8,169 |
|
|
|
19,117 |
|
|
|
14,911 |
|
Selling, general and administrative |
|
31,353 |
|
|
|
24,080 |
|
|
|
63,812 |
|
|
|
50,119 |
|
Other lease costs |
|
296 |
|
|
|
927 |
|
|
|
584 |
|
|
|
1,851 |
|
Impairment and restructuring costs |
|
7,670 |
|
|
|
— |
|
|
|
7,670 |
|
|
|
— |
|
Total operating expenses |
|
48,400 |
|
|
|
33,176 |
|
|
|
91,183 |
|
|
|
66,881 |
|
Loss from operations |
|
(37,100 |
) |
|
|
(10,942 |
) |
|
|
(63,467 |
) |
|
|
(26,099 |
) |
Other income (expense): |
|
|
|
|
|
|
|
||||||||
Interest income |
|
2,692 |
|
|
|
3,681 |
|
|
|
5,962 |
|
|
|
7,629 |
|
Change in fair value of contingent consideration |
|
4,273 |
|
|
|
— |
|
|
|
3,894 |
|
|
|
— |
|
Other income (expense), net |
|
49 |
|
|
|
(9 |
) |
|
|
108 |
|
|
|
217 |
|
Loss before income taxes |
|
(30,086 |
) |
|
|
(7,270 |
) |
|
|
(53,503 |
) |
|
|
(18,253 |
) |
Income tax benefit (expense) |
|
73 |
|
|
|
(117 |
) |
|
|
2,986 |
|
|
|
(297 |
) |
Net loss |
$ |
(30,013 |
) |
|
$ |
(7,387 |
) |
|
$ |
(50,517 |
) |
|
$ |
(18,550 |
) |
|
|
|
|
|
|
|
|
||||||||
Net loss per common share, basic and diluted |
$ |
(0.77 |
) |
|
$ |
(0.19 |
) |
|
$ |
(1.30 |
) |
|
$ |
(0.49 |
) |
|
|
|
|
|
|
|
|
||||||||
Weighted-average common shares outstanding, basic and diluted |
|
38,893 |
|
|
|
38,338 |
|
|
|
38,801 |
|
|
|
38,232 |
|
QUANTERIX CORPORATION CONSOLIDATED BALANCE SHEETS (amounts in thousands, except per share data, unaudited) |
|||||
|
June 30, 2025 |
|
December 31, 2024 |
||
ASSETS |
|
|
|
||
Current assets: |
|
|
|
||
Cash and cash equivalents |
$ |
132,896 |
|
$ |
56,709 |
Marketable securities |
|
128,276 |
|
$ |
232,413 |
Accounts receivable, net of allowance for expected credit losses |
|
23,549 |
|
$ |
32,141 |
Inventory |
|
30,142 |
|
$ |
32,775 |
Prepaid expenses and other current assets |
|
7,254 |
|
$ |
9,556 |
Total current assets |
|
322,117 |
|
|
363,594 |
Restricted cash |
|
2,641 |
|
$ |
2,610 |
Property and equipment, net |
|
15,748 |
|
$ |
17,150 |
Intangible assets, net |
|
16,332 |
|
$ |
4,031 |
Operating lease right-of-use assets |
|
15,710 |
|
$ |
16,339 |
Other non-current assets |
|
3,061 |
|
$ |
2,809 |
Total assets |
$ |
375,609 |
|
$ |
406,533 |
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
||
Current liabilities: |
|
|
|
||
Accounts payable |
$ |
9,124 |
|
$ |
6,953 |
Accrued compensation and benefits |
|
9,110 |
|
$ |
12,620 |
Accrued expenses and other current liabilities |
|
15,388 |
|
$ |
8,851 |
Deferred revenue |
|
9,427 |
|
$ |
8,827 |
Operating lease liabilities |
|
5,153 |
|
$ |
4,756 |
Total current liabilities |
|
48,202 |
|
|
42,007 |
Deferred revenue, net of current portion |
|
1,056 |
|
$ |
1,073 |
Operating lease liabilities, net of current portion |
|
30,381 |
|
$ |
32,615 |
Non-current portion of contingent consideration |
|
2,718 |
|
$ |
— |
Other non-current liabilities |
|
794 |
|
$ |
800 |
Total liabilities |
|
83,151 |
|
|
76,495 |
Total stockholders’ equity |
|
292,458 |
|
|
330,038 |
Total liabilities and stockholders’ equity |
$ |
375,609 |
|
$ |
406,533 |
QUANTERIX CORPORATION CONSOLIDATED STATEMENTS OF CASH FLOWS (amounts in thousands, unaudited) |
|||||||
|
Six Months Ended June 30, |
||||||
|
|
2025 |
|
|
|
2024 |
|
Cash flows from operating activities: |
|
|
|
||||
Net loss |
$ |
(50,517 |
) |
|
$ |
(18,550 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
||||
Depreciation and amortization expense |
|
4,187 |
|
|
$ |
3,124 |
|
Credit losses on accounts receivable |
|
(262 |
) |
|
$ |
676 |
|
Accretion of marketable securities |
|
(1,567 |
) |
|
|
(3,619 |
) |
Impairment of goodwill |
|
6,374 |
|
|
|
— |
|
Operating lease right-of-use asset amortization |
|
850 |
|
|
|
840 |
|
Stock-based compensation expense |
|
10,834 |
|
|
|
10,493 |
|
Change in fair value of contingent consideration |
|
(3,894 |
) |
|
|
— |
|
Other operating activity |
|
(370 |
) |
|
|
(13 |
) |
Changes in assets and liabilities: |
|
|
|
||||
Accounts receivable |
|
9,476 |
|
|
|
(7,242 |
) |
Inventory |
|
2,993 |
|
|
|
(7,083 |
) |
Prepaid expenses and other current assets |
|
1,942 |
|
|
|
597 |
|
Other non-current assets |
|
(147 |
) |
|
|
(599 |
) |
Accounts payable |
|
2,796 |
|
|
|
2,054 |
|
Accrued compensation and benefits, accrued expenses, and other current liabilities |
|
1,605 |
|
|
|
(4,310 |
) |
Deferred revenue |
|
583 |
|
|
|
354 |
|
Operating lease liabilities |
|
(2,058 |
) |
|
|
(1,876 |
) |
Other non-current liabilities |
|
(2,368 |
) |
|
|
39 |
|
Net cash used in operating activities |
|
(19,543 |
) |
|
|
(25,115 |
) |
Cash flows from investing activities: |
|
|
|
||||
Purchases of marketable securities |
|
(30,245 |
) |
|
|
(189,344 |
) |
Proceeds from sales and maturities of marketable securities |
|
135,874 |
|
|
|
89,229 |
|
Purchases of property and equipment |
|
(2,033 |
) |
|
|
(2,105 |
) |
Acquisition, net of cash acquired |
|
(8,954 |
) |
|
|
— |
|
Net cash provided by (used in) investing activities |
|
94,642 |
|
|
|
(102,220 |
) |
Cash flows from financing activities: |
|
|
|
||||
Proceeds from common stock issued under stock plans |
|
668 |
|
|
|
2,421 |
|
Payments for employee taxes withheld on stock-based compensation awards |
|
(1,004 |
) |
|
|
(2,150 |
) |
Net cash provided by (used in) financing activities |
|
(336 |
) |
|
|
271 |
|
Net increase (decrease) in cash, cash equivalents, and restricted cash |
|
74,763 |
|
|
|
(127,064 |
) |
Effect of exchange rate changes on cash, cash equivalents, and restricted cash |
|
1,455 |
|
|
|
(353 |
) |
Cash, cash equivalents, and restricted cash at beginning of period |
|
59,319 |
|
|
|
177,026 |
|
Cash, cash equivalents, and restricted cash at end of period |
$ |
135,537 |
|
|
$ |
49,609 |
|
Use of Non-GAAP Financial Measures
To supplement our financial statements presented on a
- Adjusted EBITDA and adjusted EBITDA margin: We define adjusted EBITDA as net income (loss) adjusted to exclude interest income, income tax (expense) benefit, depreciation and amortization expense, stock-based compensation expense, acquisition and integration related costs, impairment and restructuring, and certain other items which include other charges or benefits resulting from transactions or events that are highly variable, significant in size, and that we do not believe are indicative of ongoing or future business operations. These items are discussed in more detail below the tables reconciling the GAAP to non-GAAP measures. Adjusted EBITDA margin is calculated as adjusted EBITDA divided by total revenues.
- Adjusted gross profit, adjusted gross margin, adjusted total operating expenses, and adjusted loss from operations: We calculate these non-GAAP financial measures by including shipping and handling costs for product sales within cost of product revenue instead of within selling, general and administrative expenses. Additionally, we exclude amortization of certain acquired intangible assets, acquisition and integration related costs, and certain other items which include other charges or benefits resulting from transactions or events that are highly variable, significant in size, and that we do not believe are indicative of ongoing or future business operations. Adjusted gross margin is calculated as adjusted gross profit divided by total revenues.
- Adjusted cash usage: We calculate cash usage as the total change in cash, cash equivalents, and restricted cash adjusted to include the net change from purchases, sales, and maturities of marketable securities (excluding any interest receivable). Adjusted cash usage is calculated as cash usage further adjusted to exclude cash payments related to transactions or events that are highly variable, significant in size, and that we do not believe are indicative of ongoing or future business operations.
We believe that presentation of these non-GAAP financial measures provides supplemental information useful to investors in understanding our underlying operating results and trends. We use these non-GAAP financial measures to evaluate our operating performance in a manner that allows for meaningful period-to-period comparison and analysis of trends in our business and our competitors. We believe that presentation of these non-GAAP financial measures provides useful information to investors in assessing our operating performance within our industry and to allow comparability with the presentation of other companies in our industry.
The non-GAAP financial measures presented here should be considered in conjunction with, and not as a substitute for, the financial information presented in accordance with
Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures set forth in the tables captioned “Reconciliation of GAAP to Non-GAAP Financial Measures” in the section below.
Additionally, we make certain forward-looking statements about our future financial performance that include non-GAAP financial measures, which are difficult to predict for future periods because the nature of the adjustments pertains to events that have not yet occurred. We do not forecast many of the excluded items for internal use and therefore information reconciling forward-looking non-GAAP financial measures to
QUANTERIX CORPORATION RECONCILIATIONS OF GAAP TO NON-GAAP FINANCIAL MEASURES
Reconciliation of Net Loss to Adjusted EBITDA (non-GAAP) and Adjusted EBITDA Margin (non-GAAP) (Unaudited, amounts in thousands except percentages) |
|||||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
Net loss |
$ |
(30,013 |
) |
|
$ |
(7,387 |
) |
|
$ |
(50,517 |
) |
|
$ |
(18,550 |
) |
Interest income |
|
(2,692 |
) |
|
|
(3,681 |
) |
|
|
(5,962 |
) |
|
|
(7,629 |
) |
Income tax expense (benefit) |
|
(73 |
) |
|
|
117 |
|
|
|
(2,986 |
) |
|
|
297 |
|
Depreciation and amortization |
|
1,999 |
|
|
|
1,601 |
|
|
|
4,187 |
|
|
|
3,124 |
|
Stock-based compensation expense |
|
5,373 |
|
|
|
5,228 |
|
|
|
10,834 |
|
|
|
10,493 |
|
Acquisition and integration related costs (1) |
|
4,139 |
|
|
|
— |
|
|
|
7,717 |
|
|
|
— |
|
Earnout recorded as compensation expense (2) |
|
4,156 |
|
|
|
— |
|
|
|
7,900 |
|
|
|
— |
|
Changes in contingent consideration (3) |
|
(4,273 |
) |
|
|
— |
|
|
|
(3,894 |
) |
|
|
— |
|
Impairment and restructuring costs (4) |
|
7,670 |
|
|
|
— |
|
|
|
7,670 |
|
|
|
— |
|
Adjusted EBITDA (non-GAAP) |
$ |
(13,714 |
) |
|
$ |
(4,122 |
) |
|
$ |
(25,051 |
) |
|
$ |
(12,265 |
) |
|
|
|
|
|
|
|
|
||||||||
Total revenues |
$ |
24,476 |
|
|
$ |
34,381 |
|
|
$ |
54,810 |
|
|
$ |
66,447 |
|
Adjusted EBITDA margin (non-GAAP) (adjusted EBITDA as a % of revenue) |
|
(56.0 |
)% |
|
|
(12.0 |
)% |
|
|
(45.7 |
)% |
|
|
(18.5 |
)% |
| (1) | Represents acquisition and integration costs directly related to the Company's business combinations. Acquisition costs include professional fees supporting due diligence, legal, and accounting activities to execute a transaction. Integration costs include third party and internal direct costs to integrate acquired companies, employees, and their customers. |
(2) |
Consists of the earnout recognized as compensation expense related to the Emission acquisition. |
(3) |
Consists of fair value adjustments for the contingent consideration liability related to the Emission acquisition. |
(4) |
Represents impairment of goodwill and severance and related benefit costs from restructuring plans announced in 2025. |
Reconciliation of Net Increase in Cash, Cash Equivalents, and Restricted Cash to Adjusted Cash Usage (non-GAAP) (Unaudited, amounts in thousands) |
|||||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
Net increase (decrease) in cash, cash equivalents, and restricted cash |
$ |
55,796 |
|
|
$ |
1,696 |
|
|
$ |
74,763 |
|
|
$ |
(127,064 |
) |
Effect of exchange rate changes on cash, cash equivalents, and restricted cash |
|
594 |
|
|
|
27 |
|
|
|
1,455 |
|
|
|
(353 |
) |
Net change in marketable securities |
|
(62,093 |
) |
|
|
(6,787 |
) |
|
|
(104,137 |
) |
|
|
102,951 |
|
Cash usage |
|
(5,703 |
) |
|
|
(5,064 |
) |
|
|
(27,919 |
) |
|
|
(24,466 |
) |
Adjustments: |
|
|
|
|
|
|
|
||||||||
Acquisition and integration related (1) |
|
1,987 |
|
|
|
— |
|
|
|
14,077 |
|
|
|
— |
|
Restructuring costs (2) |
|
1,073 |
|
|
|
— |
|
|
|
1,073 |
|
|
|
— |
|
Restatement related (3) |
|
— |
|
|
|
— |
|
|
|
1,102 |
|
|
|
— |
|
Adjusted cash usage (non-GAAP) |
$ |
(2,643 |
) |
|
$ |
(5,064 |
) |
|
$ |
(11,667 |
) |
|
$ |
(24,466 |
) |
(1) |
Represents cash payments towards acquisition and integration related activities, including the cash purchase price of a business. |
(2) |
Represents cash payments for severance and related benefits from restructuring plans announced in 2025. |
(3) |
Payment of costs associated with the restatement of previously issued financial statements that was completed at the end of 2024. |
Reconciliation of Gross Profit, Gross Margin, Total Operating Expenses and Loss from Operations to Non-GAAP Financial Measures (Unaudited, amounts in thousands except percentages) |
|||||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
|
2025 |
|
|
|
2024 |
|
|
|
2025 |
|
|
|
2024 |
|
Gross profit |
$ |
11,300 |
|
|
$ |
22,234 |
|
|
$ |
27,716 |
|
|
$ |
40,782 |
|
Shipping and handling costs |
|
(1,299 |
) |
|
|
(2,075 |
) |
|
|
(2,876 |
) |
|
|
(4,217 |
) |
Amortization of acquired intangible assets (1) |
|
234 |
|
|
|
— |
|
|
|
461 |
|
|
|
— |
|
Adjusted gross profit (non-GAAP) |
$ |
10,235 |
|
|
$ |
20,159 |
|
|
$ |
25,301 |
|
|
$ |
36,565 |
|
|
|
|
|
|
|
|
|
||||||||
Total revenues |
$ |
24,476 |
|
|
$ |
34,381 |
|
|
$ |
54,810 |
|
|
$ |
66,447 |
|
Gross margin (gross profit as % of total revenues) |
|
46.2 |
% |
|
|
64.7 |
% |
|
|
50.6 |
% |
|
|
61.4 |
% |
Adjusted gross margin (non-GAAP) (adjusted gross profit as % of total revenues) |
|
41.8 |
% |
|
|
58.6 |
% |
|
|
46.2 |
% |
|
|
55.0 |
% |
|
|
|
|
|
|
|
|
||||||||
Total operating expenses |
$ |
48,400 |
|
|
$ |
33,176 |
|
|
$ |
91,183 |
|
|
$ |
66,881 |
|
Shipping and handling costs |
|
(1,299 |
) |
|
|
(2,075 |
) |
|
|
(2,876 |
) |
|
|
(4,217 |
) |
Acquisition and integration related costs (2) |
|
(4,139 |
) |
|
|
— |
|
|
|
(7,717 |
) |
|
|
— |
|
Earnout recorded as compensation expense (3) |
|
(4,156 |
) |
|
|
— |
|
|
|
(7,900 |
) |
|
|
— |
|
Impairment and restructuring costs (4) |
|
(7,670 |
) |
|
|
— |
|
|
|
(7,670 |
) |
|
|
— |
|
Adjusted total operating expenses (non-GAAP) |
$ |
31,136 |
|
|
$ |
31,101 |
|
|
$ |
65,020 |
|
|
$ |
62,664 |
|
|
|
|
|
|
|
|
|
||||||||
Loss from operations |
$ |
(37,100 |
) |
|
$ |
(10,942 |
) |
|
$ |
(63,467 |
) |
|
$ |
(26,099 |
) |
Amortization of acquired intangible assets (1) |
|
234 |
|
|
|
— |
|
|
|
461 |
|
|
|
— |
|
Acquisition and integration related costs (2) |
|
4,139 |
|
|
|
— |
|
|
|
7,717 |
|
|
|
— |
|
Earnout recorded as compensation expense (3) |
|
4,156 |
|
|
|
— |
|
|
|
7,900 |
|
|
|
— |
|
Impairment and restructuring costs (4) |
|
7,670 |
|
|
|
— |
|
|
|
7,670 |
|
|
|
— |
|
Adjusted loss from operations (non-GAAP) |
$ |
(20,901 |
) |
|
$ |
(10,942 |
) |
|
$ |
(39,719 |
) |
|
$ |
(26,099 |
) |
(1) |
Consists only of the amortization of intangible assets acquired in 2025. |
(2) |
Represents acquisition and integration costs directly related to the Company's business combinations. Acquisition costs include professional fees supporting due diligence, legal, and accounting activities to execute a transaction. Integration costs include third party and internal direct costs to integrate acquired companies, employees, and their customers. |
(3) |
Consists of the earnout recognized as compensation expense related to the Emission acquisition. |
(4) |
Represents impairment of goodwill and severance and related benefit costs from restructuring plans announced in 2025. |
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
Statements included in this press release that are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements about Quanterix’s future business outlook, operations, strategy and financial performance, including statements under the header “2025 Full Year Business Outlook.”. Words and phrases such as “may,” “approximately,” “continue,” “should,” “expects,” “projects,” “anticipates,” “is likely,” “look ahead,” “look forward,” “believes,” “will,” “intends,” “estimates,” “strategy,” “plan,” “could,” “potential,” “possible” and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are subject to certain risks and uncertainties that are difficult to predict with regard to, among other things, timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results. Such risks and uncertainties include, among others, the following possibilities with respect to Quanterix’s future business, operations, strategy and financial performance: risks related to the impact of recent
All forward-looking statements, expressed or implied, included in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to herein. If one or more events related to these or other risks or uncertainties materialize, or if Quanterix’s underlying assumptions prove to be incorrect, actual results may differ materially from what Quanterix anticipates. Quanterix cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made and are based on information available at that time. Quanterix does not assume any obligation to update or otherwise revise any forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by federal securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250807792685/en/
Media Contact:
Marissa Klaassen
(978) 488-1854
media@quanterix.com
Investor Relations Contact:
Joshua Young
(508) 846-3327
ir@quanterix.com
Source: Quanterix Corporation
